OCP/DARS new clinical studies IDIQ 5 year contract with M ceiling
Past New Requirement Updated
- Agency
-
Food and Drug Administration
Department of Health and Human Services
- Solicitation expected
- Estimated value
- $50,000,000 to $100,000,000
- Set-aside
- No set-aside
Forecast facts
- Anticipated award
- NAICS code
- 541714 Research and Development in Biotechnology (except Nanobiotechnology)
- Points of contact
-
- CDER Acquisition Liaison cderacquisitions@fda.hhs.gov
Forecast details come from HHS's procurement forecast. Agencies' dates and values are estimates.
About this forecast
The Food and Drug Administration is seeking a contractor to support new clinical studies under a five-year Indefinite Delivery/Indefinite Quantity (IDIQ) contract. This research and development effort in biotechnology will be procured without a set-aside restriction. The solicitation is estimated to be released on July 1, 2025, with an anticipated contract award date of January 1, 2026.
The estimated award value for this contract ranges from $50 million to $100 million over the five-year performance period. Interested contractors in the biotechnology research and development sector should direct inquiries to the FDA's Acquisition Liaison at cderacquisitions@fda.hhs.gov. This opportunity falls under NAICS code 541714 for Research and Development in Biotechnology (except Nanobiotechnology).
Forecast text
OCP/DARS new clinical studies IDIQ 5 year contract to support new clinical studies
5 year IDIQ w/50mil ceiling.
On GovTribe
Work this forecast
- Track it in your pipeline
- Find teaming partners
- Similar forecasts
- Ask GovTribe AI about this forecast